Open now for participants who have completed any prior OV101 study, including the STARS study. 

ELARA is an extension study that will enable individuals with Angelman syndrome who completed any prior OV101 study to be eligible to receive the investigational medicine. The study will use once-daily dosing and will assess long term safety and tolerability in addition to efficacy measures.

Please contact the site location that you participated in during STARS OV101 (see list below) and the clinical study team you worked with during STARS can tell you exactly how to enroll in ELARA. 

San Diego
Phone: 858-576-1700 ext. 22613  |  Email: mnsuarez@rchsd.org

Boston
Phone: 617-919-6008  |  Email: Catherine.merton@childrens.harvard.edu

Cincinnati
Phone: 503-803-7226  |  Email: kaela.obrien@cchmc.org

Phoenix
Phone: 602-218-8225  |  Email: soberreynolds@autismcenter.org

Nashville
Phone: 615-875-9700  |  Phone #2: 615-936-6702

Chicago
Phone: 312-563-6636  |  Email: Melissa_r_baer@rush.edu

Atlanta
Phone: 404-778-8562  |  Email: jean.luan@emory.edu

Philadelphia
Phone: 610-891-9024  |  Email: apatel@suburbanresearch.com

 

If you are having trouble reaching the team, please contact ELARA@ovidrx.com.

The study is sponsored by Ovid Therapeutics, a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

The Angelman Syndrome Foundation does not endorse any clinical trial or study, but provides information to the AS community for its own consideration.